Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
The Readout

A CEO smackdown & good news (maybe) for cholesterol drugs 

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Dec. 2, 2016

Reprints
The READOUT
Alex Hogan/STAT

The Readout for December 02, 2016

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Newly available test strips can detect lethal ‘tranq’ in…
Newly available test strips can detect lethal ‘tranq’ in drug supply
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
How Biogen got Aduhelm approved, Sanofi’s future in mRNA,…
How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga

Recommended Stories